New Leaf Venture Partners Revenue and Competitors

Location

N/A

Total Funding

VC/PE

Industry

Estimated Revenue & Valuation

  • New Leaf Venture Partners's estimated annual revenue is currently $15M per year.(i)
  • New Leaf Venture Partners's estimated revenue per employee is $882,353

Employee Data

  • New Leaf Venture Partners has 17 Employees.(i)
  • New Leaf Venture Partners grew their employee count by 6% last year.

New Leaf Venture Partners's People

NameTitleEmail/Phone
1
Managing Director New YorkReveal Email/Phone
2
managing directorReveal Email/Phone
3
Chief Operating Officer and Chief Financial OfficerReveal Email/Phone
4
Managing DirectorReveal Email/Phone
5
Venture PartnerReveal Email/Phone
6
Senior Advisor,Reveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$3.5M180%N/AN/A
#2
N/A19-21%N/AN/A
#3
$7.5M5721%N/AN/A
#4
$11830M3644%$1MN/A
#5
$7.5M4850%$48.1MN/A
#6
$15M12317%N/AN/A
#7
N/A8-88%N/AN/A
#8
N/A24-11%N/AN/A
#9
N/A1614%N/AN/A
#10
$7.5M5320%N/AN/A
Add Company

What Is New Leaf Venture Partners?

New Leaf Venture Partners was formed in 2005, when the healthcare team spun out from the Sprout Group, the venture capital affiliate of Credit Suisse. The NLV team has been built over more than 15 years and has managed the health care technology portfolios in five Sprout funds as well as in two of its own NLV funds

keywords:N/A

N/A

Total Funding

17

Number of Employees

$15M

Revenue (est)

6%

Employee Growth %

N/A

Valuation

N/A

Accelerator

New Leaf Venture Partners News

2022-04-20 - People moves: Aviva Investors fills new head of LDI and ...

Aviva Investors, PFA, Sarasin, LOIM, Zurich, Ninety One, Casey Quirk, Reframe Capital, Industriens Pension.

2022-03-30 - Pfizer to Buy ReViral, For Up To $525M

Backers in the company included CR-CP Life Science Fund, Andera Partners, Brace Pharma Capital, Green Sands Equity, New Leaf Venture...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$1.5M17-62%N/A
#2
$1.5M17-11%N/A
#3
$2.1M17-26%N/A
#4
$4.9M17-19%$19.4M
#5
$7.5M17-19%$56.6M